Apyx Medical Q1 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Source: seekingalpha
- Earnings Highlights: Apyx Medical reported a Q1 GAAP EPS of -$0.05, beating expectations by $0.06, with revenue of $12.5 million reflecting a 32.6% year-over-year increase, surpassing forecasts by $1.73 million, indicating strong market performance.
- Upward Revision of 2026 Guidance: The company raised its total revenue guidance for 2026 to a range of $59.0 million to $60.0 million, up from the previous $57.5 million to $58.5 million, reflecting confidence in future growth prospects.
- Segment Revenue Expectations: Surgical Aesthetics revenue is projected between $54.0 million and $55.0 million, an increase from the prior guidance of $53.0 million to $54.0 million, while OEM revenue is expected to be approximately $5.0 million, up from $4.5 million, showcasing robust growth across business lines.
- Cost Control Measures: The company anticipates operating expenses to remain below $45.0 million for 2026, ensuring that it maintains cost control while driving revenue growth, thereby enhancing overall profitability and financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APYX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APYX
Wall Street analysts forecast APYX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.090
Low
6.00
Averages
7.00
High
8.00
Current: 4.090
Low
6.00
Averages
7.00
High
8.00
About APYX
Apyx Medical, Inc., formerly Apyx Medical Corporation, is a surgical aesthetics company. Its segments include Advanced Energy and Original Equipment Manufacturer (OEM). The Advanced Energy segment’s product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It focuses on the cosmetic surgery market, where Renuvion offers plastic surgeons, facial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. These product lines consist of a multifunction generator, a handpiece and a supply of helium gas. Through OEM agreements, the OEM segment, designs, develops and manufactures electrosurgical equipment and medical devices by producing generators, medical devices and related accessories for medical device manufacturers as well as start-up businesses in need of its energy-based designs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Apyx Medical Showcases New Technology at Miami Swim Week
- Technology Innovation Showcase: Apyx Medical will present its next-generation body contouring system, AYON, at Miami Swim Week, integrating Renuvion and various advanced fat removal technologies to enhance surgeons' treatment flexibility and workflow efficiency, thereby addressing the growing demand for body contouring.
- Real Patient Transformations: The event will feature real Renuvion patients walking the runway, showcasing their confidence and transformations achieved through advanced aesthetic procedures, emphasizing the company's commitment to reshaping beauty standards and delivering authentic results.
- Market Demand Response: As patients increasingly seek comprehensive solutions and natural outcomes, Apyx Medical's Body by Apyx event reflects its keen insight into market changes, aiming to attract more clients through real transformation stories.
- Industry Leadership: AYON, as an FDA-cleared innovative system, combines precision and versatility, marking Apyx Medical's leadership in the surgical aesthetics field, and is expected to provide surgeons with higher returns on investment and consistent treatment outcomes.
See More
Apyx Medical Showcases New Technology at Miami Swim Week
- Product Innovation Showcase: Apyx Medical will present its next-generation body contouring system, AYON, at Miami Swim Week, integrating Renuvion and various advanced fat removal technologies to enhance surgeons' treatment flexibility and workflow efficiency, thereby addressing the growing demand for body contouring.
- Real Case Presentations: The event will feature real patient transformation stories, showcasing the latest outcomes in body contouring and emphasizing Apyx Medical's contribution to reshaping beauty standards, further enhancing brand recognition and customer trust.
- Market Demand Response: As patients increasingly seek more comprehensive and natural body contouring solutions, Apyx Medical's Body by Apyx event demonstrates its keen insight into market changes, aiming to attract more clients through authentic transformation stories.
- Integrated Technology Advantages: The AYON system combines precision, versatility, and innovation, offering real-time adjustments with LIFT technology and Renuvion's tissue contraction capabilities, helping surgeons achieve higher treatment outcomes and return on investment, marking a revolutionary advancement in the body contouring field.
See More
Apyx Medical Receives Expanded Clearance for AYON System
- FDA Clearance Expansion: Apyx Medical Corporation has received expanded 510(k) clearance from the FDA for its AYON Body Contouring System to include power liposuction, enhancing fat removal efficiency and reducing surgeon effort and operating room time, establishing the system as the gold standard in surgical aesthetics.
- Commercial Launch Plan: The company plans to initiate a limited commercial launch of the power liposuction function, aiming to work closely with early adopters to refine training and customer experience, thereby laying the groundwork for future commercial scaling and enhancing market competitiveness.
- Integrated Platform Benefits: The AYON system integrates fat removal, closed-loop contouring, and Renuvion tissue contraction capabilities, enabling surgeons to perform multiple critical body contouring procedures within one system, significantly streamlining workflow and improving procedural efficiency.
- Innovative Technology Leadership: With features like LIFT Technology for real-time adjustments and enhanced tissue contraction via Renuvion, the AYON system ensures optimal patient outcomes in surgical procedures, further solidifying Apyx Medical's leadership position in the aesthetic surgery market.
See More
Apyx Medical Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: Apyx Medical reported total revenue of $12.5 million in Q1 2026, a 33% increase from $9.4 million in the same period last year, primarily driven by a 36% rise in Surgical Aesthetics product sales, indicating strong market performance.
- Strong Product Demand: The AYON body contouring system continues to see robust sales in the U.S., contributing to Surgical Aesthetics revenue of $10.7 million, with FDA clearance for power liposuction anticipated this quarter, further expanding market potential.
- Optimistic Financial Outlook: The company raised its total revenue guidance for 2026 to a range of $59 million to $60 million, up from the previous guidance of $57.5 million to $58.5 million, reflecting confidence in future performance.
- Effective Cost Control: Despite tariff pressures, Apyx anticipates gross margins of approximately 62% to 63% for the year, with total operating expenses not exceeding $45 million, demonstrating effective cost management strategies.
See More
Apyx Medical Q1 Earnings Exceed Expectations
- Earnings Highlights: Apyx Medical reported a Q1 GAAP EPS of -$0.05, beating expectations by $0.06, with revenue of $12.5 million reflecting a 32.6% year-over-year increase, surpassing forecasts by $1.73 million, indicating strong market performance.
- Upward Revision of 2026 Guidance: The company raised its total revenue guidance for 2026 to a range of $59.0 million to $60.0 million, up from the previous $57.5 million to $58.5 million, reflecting confidence in future growth prospects.
- Segment Revenue Expectations: Surgical Aesthetics revenue is projected between $54.0 million and $55.0 million, an increase from the prior guidance of $53.0 million to $54.0 million, while OEM revenue is expected to be approximately $5.0 million, up from $4.5 million, showcasing robust growth across business lines.
- Cost Control Measures: The company anticipates operating expenses to remain below $45.0 million for 2026, ensuring that it maintains cost control while driving revenue growth, thereby enhancing overall profitability and financial health.
See More
Renuvion Wins Best Minimally Invasive Skin Tightener Award Again
- Award Recognition: Renuvion has been named the 'Best Minimally Invasive Skin Tightener' for the second consecutive year, reflecting its leadership in surgical aesthetics and enhancing trust among physicians and patients, thereby boosting brand recognition in the market.
- Technological Edge: As the only FDA-cleared device for use after liposuction, Renuvion, combined with the AYON platform, improves physician workflow efficiency and treatment customization, further expanding the company's market share in body contouring.
- Industry Trust: A 2024 Wakefield Research survey indicates that 80% of surgeons consider Renuvion the most trusted body contouring technology, a statistic that not only enhances product competitiveness but also lays a foundation for future sales growth.
- Innovation Commitment: Apyx Medical is dedicated to improving patients' lives through its Helium Plasma Platform Technology, with over 90 clinical publications supporting the effectiveness of Renuvion and J-Plasma, further solidifying its leadership position in the cosmetic surgery market.
See More
Apyx Medical Showcases New Technology at Miami Swim Week
- Technology Innovation Showcase: Apyx Medical will present its next-generation body contouring system, AYON, at Miami Swim Week, integrating Renuvion and various advanced fat removal technologies to enhance surgeons' treatment flexibility and workflow efficiency, thereby addressing the growing demand for body contouring.
- Real Patient Transformations: The event will feature real Renuvion patients walking the runway, showcasing their confidence and transformations achieved through advanced aesthetic procedures, emphasizing the company's commitment to reshaping beauty standards and delivering authentic results.
- Market Demand Response: As patients increasingly seek comprehensive solutions and natural outcomes, Apyx Medical's Body by Apyx event reflects its keen insight into market changes, aiming to attract more clients through real transformation stories.
- Industry Leadership: AYON, as an FDA-cleared innovative system, combines precision and versatility, marking Apyx Medical's leadership in the surgical aesthetics field, and is expected to provide surgeons with higher returns on investment and consistent treatment outcomes.
See More
Apyx Medical Showcases New Technology at Miami Swim Week
- Product Innovation Showcase: Apyx Medical will present its next-generation body contouring system, AYON, at Miami Swim Week, integrating Renuvion and various advanced fat removal technologies to enhance surgeons' treatment flexibility and workflow efficiency, thereby addressing the growing demand for body contouring.
- Real Case Presentations: The event will feature real patient transformation stories, showcasing the latest outcomes in body contouring and emphasizing Apyx Medical's contribution to reshaping beauty standards, further enhancing brand recognition and customer trust.
- Market Demand Response: As patients increasingly seek more comprehensive and natural body contouring solutions, Apyx Medical's Body by Apyx event demonstrates its keen insight into market changes, aiming to attract more clients through authentic transformation stories.
- Integrated Technology Advantages: The AYON system combines precision, versatility, and innovation, offering real-time adjustments with LIFT technology and Renuvion's tissue contraction capabilities, helping surgeons achieve higher treatment outcomes and return on investment, marking a revolutionary advancement in the body contouring field.
See More
Apyx Medical Receives Expanded Clearance for AYON System
- FDA Clearance Expansion: Apyx Medical Corporation has received expanded 510(k) clearance from the FDA for its AYON Body Contouring System to include power liposuction, enhancing fat removal efficiency and reducing surgeon effort and operating room time, establishing the system as the gold standard in surgical aesthetics.
- Commercial Launch Plan: The company plans to initiate a limited commercial launch of the power liposuction function, aiming to work closely with early adopters to refine training and customer experience, thereby laying the groundwork for future commercial scaling and enhancing market competitiveness.
- Integrated Platform Benefits: The AYON system integrates fat removal, closed-loop contouring, and Renuvion tissue contraction capabilities, enabling surgeons to perform multiple critical body contouring procedures within one system, significantly streamlining workflow and improving procedural efficiency.
- Innovative Technology Leadership: With features like LIFT Technology for real-time adjustments and enhanced tissue contraction via Renuvion, the AYON system ensures optimal patient outcomes in surgical procedures, further solidifying Apyx Medical's leadership position in the aesthetic surgery market.
See More
Apyx Medical Reports Strong Q1 2026 Earnings with Revenue Growth
- Significant Revenue Growth: Apyx Medical reported total revenue of $12.5 million in Q1 2026, a 33% increase from $9.4 million in the same period last year, primarily driven by a 36% rise in Surgical Aesthetics product sales, indicating strong market performance.
- Strong Product Demand: The AYON body contouring system continues to see robust sales in the U.S., contributing to Surgical Aesthetics revenue of $10.7 million, with FDA clearance for power liposuction anticipated this quarter, further expanding market potential.
- Optimistic Financial Outlook: The company raised its total revenue guidance for 2026 to a range of $59 million to $60 million, up from the previous guidance of $57.5 million to $58.5 million, reflecting confidence in future performance.
- Effective Cost Control: Despite tariff pressures, Apyx anticipates gross margins of approximately 62% to 63% for the year, with total operating expenses not exceeding $45 million, demonstrating effective cost management strategies.
See More
Apyx Medical Q1 Earnings Exceed Expectations
- Earnings Highlights: Apyx Medical reported a Q1 GAAP EPS of -$0.05, beating expectations by $0.06, with revenue of $12.5 million reflecting a 32.6% year-over-year increase, surpassing forecasts by $1.73 million, indicating strong market performance.
- Upward Revision of 2026 Guidance: The company raised its total revenue guidance for 2026 to a range of $59.0 million to $60.0 million, up from the previous $57.5 million to $58.5 million, reflecting confidence in future growth prospects.
- Segment Revenue Expectations: Surgical Aesthetics revenue is projected between $54.0 million and $55.0 million, an increase from the prior guidance of $53.0 million to $54.0 million, while OEM revenue is expected to be approximately $5.0 million, up from $4.5 million, showcasing robust growth across business lines.
- Cost Control Measures: The company anticipates operating expenses to remain below $45.0 million for 2026, ensuring that it maintains cost control while driving revenue growth, thereby enhancing overall profitability and financial health.
See More
Renuvion Wins Best Minimally Invasive Skin Tightener Award Again
- Award Recognition: Renuvion has been named the 'Best Minimally Invasive Skin Tightener' for the second consecutive year, reflecting its leadership in surgical aesthetics and enhancing trust among physicians and patients, thereby boosting brand recognition in the market.
- Technological Edge: As the only FDA-cleared device for use after liposuction, Renuvion, combined with the AYON platform, improves physician workflow efficiency and treatment customization, further expanding the company's market share in body contouring.
- Industry Trust: A 2024 Wakefield Research survey indicates that 80% of surgeons consider Renuvion the most trusted body contouring technology, a statistic that not only enhances product competitiveness but also lays a foundation for future sales growth.
- Innovation Commitment: Apyx Medical is dedicated to improving patients' lives through its Helium Plasma Platform Technology, with over 90 clinical publications supporting the effectiveness of Renuvion and J-Plasma, further solidifying its leadership position in the cosmetic surgery market.
See More
